Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a ...

Sanofi (Euronext: SAN) has announced that the UK's health technology assessor will conduct a new review of its Sarclisa ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...

Sanofi (NASDAQ:SNY) Q3 2024 Earnings Call Transcript ... Other innovative medicines like Nexviazyme, Rezurock, and Sarclisa ...

French pharmaceutical group Sanofi experienced a profitability boom in the third ... Tzield - for type 1 diabetes -, Sarclisa (multiple myeloma) and Rezurock, used in cases of graft-versus-host ...

Sanofi will keep a significant stake in the ... Another great milestone is the approval with Sarclisa in the US for adult patients with newly diagnosed multiple myeloma ineligible for transplantation.

Sanofi SNY reported third-quarter 2024 adjusted ... over year to €92 million due to generic competition. In Oncology, Sarclisa sales rose 23.7% year over year to €114 million, driven by ...

Welcome to the Q3 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide number 3. Here we have the usual forward-looking statements.